DOCSLIB.ORG

Final Program

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Final Program The 9th Annual Conference of the International Chemical Biology Society ICBS2020VIRTUAL Addressing Therapeutic Challenges Together with Chemical Biology November 11, 2020 7:30 PM to 11:30 PM EST November 12, 2020 9:30 AM to 2:00 PM EST November 13, 2020 9:30 AM to 2:40 PM EST 9th Annual Conference | November 11-13, 2020 | Virtual Table of Contents Table of Contents ............................................................ 1 Session 3: Academic-Industry Partnerships Acknowledgements ........................................................ 1 case studies .................................................................... 23 ICBS Board of Directors ................................................ 2 Session 4: Chemical Biology of Small Molecule About ICBS ...................................................................... 2 Protein Degraders ........................................................ 28 ICBS International Advisory Board ............................. 3 EFMC Speaker .............................................................. 32 ICBS Global Council ...................................................... 4 Session 5: Chemical Technologies to Promote Welcome Letter ............................................................... 5 Drug Discovery ............................................................. 33 Trainee Pre-Conference Program ................................ 6 Rising Stars Session ...................................................... 37 Detailed Program ........................................................... 7 Opening Day Trainee Forum ...................................... 41 Session 1: In-Cell Chemistry ...................................... 16 Presenter Index ............................................................. 51 Session 2: COVID-19, Disease Modeling, and Thank you to our conference sponsors ...................... 52 Drug Discovery ............................................................. 19 Acknowledgements ICBS2020 Virtual Host Biological Discovery through Chemical Innovation Initiative (BDCI), Emory University ICBS2020 Program Committee Huw Davies (co-chair), Haian Fu (co-chair), Douglas Auld, Jonathan Baell, Shuibing Chen, Jen Heemstra, Zaneta Nikolovska-Coleska, Tom Pfeifer ICBS2020 Local Organizing Committee Dennis Liotta, Jae Won Chang, Yuhong Du, M.G. Finn, Jen Heemstra, Shafiq Khan, Kojo Mensa-Wilmot, Eddie Morgan, Binghe Wang, Daqing Wu, Bill Wuest, Y. George Zheng ICBS2020 Virtual Operations Team Tiffany R. Bell-Horwath, Andrey A. Ivanov, Rachel Commander, Kun Qian, Rio Febrian ICBS2020 Trainee Forum Organizing Committee Kun Qian, Danielle Cicka, Amber Scharnow, Andre Mahoney, Ashley Modell, Jana Flegel, Jessica Nowacki, Aylin Binici, Kirujan Jeyakumar, Yuting Shuai Page 1 www.chemical-biology.org 9th Annual Conference | November 11-13, 2020 | Virtual ICBS Board of Directors Douglas S. Auld Jonathan Baell Rathnam Chaguturu (USA) President (Aus) Treasurer (USA) Haian Fu Zaneta Nikolovska-Coleska Hiroyuki Osada Chair of Board (USA) President-Elect (USA) (Japan) Tom Pfeifer Siddhartha Roy Lixin Zhang Secretary (Can) (India) Past President (China) About ICBS The International Chemical Biology Society (ICBS) is an independent, nonprofit organization dedicated to promoting research and educational opportunities at the interface of chemistry and biology. ICBS provides an important international forum that brings together cross-disciplinary scientists from academia, nonprofit organizations, government, and industry to communicate new research and help translate the power of chemical biology to advance human health. Page 2 www.chemical-biology.org 9th Annual Conference | November 11-13, 2020 | Virtual ICBS International Advisory Board Stephen Benkovic Sir Philip Cohen Jian Ding Chris Lipinski Penn State University of Dundee Shanghai Institute of Melior Discovery Materia Medica Ferid Murad Bernard Munos Litao Zhang Stuart Schreiber George Washington InnoThink Bristol-Myers Squibb Harvard University Paul Workman Tetsuo Nagano Leonard Zon Herbert Waldmann ICR-London University of Tokyo HHMI/Harvard Max Planck Institute of Molecular Physiology Junying Yuan Harvard Page 3 www.chemical-biology.org 9th Annual Conference | November 11-13, 2020 | Virtual ICBS Global Council Seung Bum Park William Pomerantz Xiaoguang Lei Sally-Ann Poulsen Mahabir Gupta Bridget Wagner Chair Co-Chair Mikiko Sodeoka Jiaoyang Jiang Ratmir Derda Changlin Tian Jason Micklefield Hanne Ingmer Christian Richard Pyane Kamyar Hadian Shi Chen Ottmann Haitao Zhang Eliezer J. Barreiro Qi Zhang Toru Kamatsu Evripidis Gavathiotis Page 4 www.chemical-biology.org 9th Annual Conference | November 11-13, 2020 | Virtual Welcome Letter Dear ICBS2020 Participants: On behalf of the ICBS leadership and the host organization, we would like to welcome each of you to this global virtual event, the 9th Annual Conference of the International Chemical Biology Society! It is an extraordinary time in the midst of the COVID-19 pandemic, which has impacted the lives of people across the world and led to major social and economic disruptions. We strongly believe that the chemical biology community can play important roles in addressing the challenges of today and beyond. Although we are unable to meet in person as we originally planned, we are excited to utilize the virtual platform to highlight the power of chemical biology to bring the community together to exchange ideas, present discoveries, and discuss emerging concepts to advance science. In particular, our program is organized to showcase the impact of collaborations and partnerships on driving chemical biology research to accelerate therapeutic discovery. We appreciate the enthusiastic participation of the thought leaders in the field as keynote speakers as they share their perspectives and inspire others. We hope that you will enjoy the presentations, thoughtfully put together by session chairs, that describe cutting edge chemical technologies and mechanistic interrogation strategies for disease biology insights. During the Opening Day Trainee Forum, which is organized by ICBS Student Chapters, ICBS2020 will feature discoveries by students and postdocs and a career discussion session to advance the professional development of trainees. We hope you will show your support and join this forum. We will also continue our tradition of showcasing emerging leaders of the field with the Rising Stars Special Session. Four outstanding ICBS Young Chemical Biologist awardees have been selected from a record number of incredible nominees. Let us come together to congratulate the rising stars of chemical biology. We would like to thank each of you, ICBS2020 participants, for your heartening response to this virtual conference. As of the day prior to ICBS2020 opening day, the number of registered participants from around the world has surpassed 1,500, representing over 50 countries and more than 300 cities. Your participation will define the success of this conference. We encourage you to engage in discussions and use the Chat and Q&A channels as well as the networking sessions to communicate with each other and the speakers. Join, connect, and inspire as a collaborative community to advance chemical biology and to address therapeutic challenges together! Enjoy the ICBS2020 Virtual Conference. Sincerely, Huw Davies, Ph.D. Professor of Chemistry, Emory University Haian Fu, Ph.D. Professor of Pharmacology & Chemical Biology, Emory University Co-Chairs, ICBS2020 Page 5 www.chemical-biology.org 9th Annual Conference | November 11-13, 2020 | Virtual 10:00 AM to 1:00 pm, November 11, 2020 (EST) Trainee Pre-Conference Program The ICBS2020 trainee forum features presentations from students and postdocs in the field of chemical biology as well as a career talk and panel discussion session with academic and industry experts! The forum aims to unite young researchers from the ICBS network, facilitate communication of new research, improve collaborative endeavors, and provide educational opportunities to the trainees in the field of chemical biology. 10:00 AM - 10:05 AM Welcome & Opening by the Trainee Forum Organizing Committee 10:05 AM - 10:55 AM Trainee Presentations Session A 10:05 AM - 10:17 AM Maria L. Adrover-Castellano, University of Michigan “Thioesterase directed evolution approach for yield improvement and expansion of the substrate scope to generate macrolactones” 10:17 AM - 10:30 AM Jiang Lan, East China University of Science and Technology “Fungal multi-functional cytochrome-P450 responsible for the biosynthesis of unprecedented BFTS-related norditerpenoids” 10:30 AM - 10:42 AM Hyungyu Lee, Emory University “Comparison of covalent delivery methods and their effects for immune-mediated killing of Helicobacter pylori” 10:42 AM - 10:55 AM Beverly Y. Mok, Broad Institute of MIT and Harvard “A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing” 11:00 AM - 11:55 PM Career Talk and Panel Discussion Dr. Colleen Keohane, Scientist, Discovery Chemistry, Janssen Dr. Luca Laraia, Assistant professor, Technical University of Denmark Dr. Kathryn Hosbein, Postdoctoral Associate & Chemistry Education Researcher, University of Michigan 12:00 PM - 1:00 PM Trainee Presentations Session B 12:00 PM - 12:12 PM Pragya Jatoo, Lead Discovery Center GmBH (LDC) “A Chemical Biology approach to decipher the Tubulin Code” 12:12 PM - 12:24 PM Dacheng Fan, University of Wisconsin-Madison “Targeted covalent inhibition of O-GlcNAc transferase in cells” 12:24 PM - 12:36 PM Shwetha Srinivasan,
Load more

Recommended publications
  • Download Issue
    Cell Circuitry || Science Teaches English || The Chicken Genome Is Hot || Magnets in Medicine SEPTEMBER 2002 www.hhmi.org/bulletin Leading Doublea Life It’s a stretch, but doctors who work bench to bedside say they wouldn’t do it any other way. FEATURES 14 On Human Terms 24 The Evolutionary War A small—some say too small—group of Efforts to undermine evolution education have physician-scientists believes the best science evolved into a 21st-century marketing cam- requires patient contact. paign that relies on legal acumen, manipulation By Marlene Cimons of scientific literature and grassroots tactics. 20 Engineering the Cell By Trisha Gura Adam Arkin sees the cell as a mechanical system. He hopes to transform molecular 28 Call of the Wild biology into a kind of cellular engineering Could quirky, new animal models help scien- and in the process, learn how to move cells tists learn how to regenerate human limbs or from sickness to health. avert the debilitating effects of a stroke? By M. Mitchell Waldrop By Kathryn Brown 24 In front of a crowd of 1,500, Ohio’s Board of Education heard testimony on whether students should learn about intelligent design in science class. DEPARTMENTS 2 NOTA BENE 33 PERSPECTIVE ulletin Intelligent Design Is a Cop-Out 4 LETTERS September 2002 || Volume 15 Number 3 NEWS AND NOTES HHMI TRUSTEES PRESIDENT’S LETTER 5 JAMES A. BAKER, III, ESQ. 34 Senior Partner, Baker & Botts A Creative Influence In from the Fields ALEXANDER G. BEARN, M.D. Executive Officer, American Philosophical Society 35 Lost on the Tip of the Tongue Adjunct Professor, The Rockefeller University UP FRONT Professor Emeritus of Medicine, Cornell University Medical College 36 Biology by Numbers FRANK WILLIAM GAY 6 Follow the Songbird Former President and Chief Executive Officer, SUMMA Corporation JAMES H.
    [Show full text]
  • The Fourth Report of Senior Pay and Perks in UK Universities History This
    Transparency at the top? The fourth report of senior pay and perks in UK universities History This is the fourth report on pay and perks at the top of British higher education institutions (HEIs) to be published by the University and College Union (UCU). It forms part of the union’s ongoing campaign for greater transparency in higher education, including the rationale behind senior pay rises. UCU submitted a Freedom of Information (FoI) request to 158 HEIs in October 2017. This followed similar requests submitted in 2016, 2015 and 2014. All requests were designed to shine a light on the arbitrary nature of senior pay and perks in universities, and support the union’s call for reform. The basis for this report The FoI request that forms the basis of this report was sent to 158 (HEIs). It requested details of vice-chancellors’ (or head of institution if known by a different title) salaries and those of other senior post-holders earning over £100,000 at the institution during the academic year of 2016/17 (1 August 2016 to 31 July 2017). It also asked for details of flights, spending on hotels, spending on expenses and if the vice-chancellor was provided with accommodation by the university. Finally, we requested to know whether or not the vice-chancellor was a member of the remuneration committee, and requested a copy of the most recently ratified minutes of the institution’s remuneration committee. Variety of responses The questions on expenditure on flights, hotels, expenses and accommodation for vice-chancellors elicited a huge variation in responses with many institutions deploying exemptions under the Freedom of Information Act to avoid providing data.
    [Show full text]
  • Us 8530498 B1 3
    USOO853 0498B1 (12) UnitedO States Patent (10) Patent No.: US 8,530,498 B1 Zeldis (45) Date of Patent: *Sep. 10, 2013 (54) METHODS FORTREATING MULTIPLE 5,639,476 A 6/1997 OShlack et al. MYELOMAWITH 5,674,533 A 10, 1997 Santus et al. 3-(4-AMINO-1-OXO-1,3-DIHYDROISOINDOL- 395 A 22 N. 2-YL)PIPERIDINE-2,6-DIONE 5,731,325 A 3/1998 Andrulis, Jr. et al. 5,733,566 A 3, 1998 Lewis (71) Applicant: Celgene Corporation, Summit, NJ (US) 5,798.368 A 8, 1998 Muller et al. 5,874.448 A 2f1999 Muller et al. (72) Inventor: Jerome B. Zeldis, Princeton, NJ (US) 5,877,200 A 3, 1999 Muller 5,929,117 A 7/1999 Muller et al. 5,955,476 A 9, 1999 Muller et al. (73) Assignee: Celgene Corporation, Summit, NJ (US) 6,020,358 A 2/2000 Muller et al. - 6,071,948 A 6/2000 D'Amato (*) Notice: Subject to any disclaimer, the term of this 6,114,355 A 9, 2000 D'Amato patent is extended or adjusted under 35 SS f 1939. All et al. U.S.C. 154(b) by 0 days. 6,235,756 B1 5/2001 D'Amatoreen et al. This patent is Subject to a terminal dis- 6,281.230 B1 8/2001 Muller et al. claimer 6,316,471 B1 1 1/2001 Muller et al. 6,326,388 B1 12/2001 Man et al. 6,335,349 B1 1/2002 Muller et al. (21) Appl. No.: 13/858,708 6,380.239 B1 4/2002 Muller et al.
    [Show full text]
  • Womencount: Leaders in Higher Education 2016
    WomenCount Leaders in Higher Education 2016 A report by Norma Jarboe OBE ‘There’s no magic about getting a good gender balance – just dogged repetition of what a high priority it is and a determination to seek out strong women candidates who could hold their own against any competition.’ WomenCount ‘If universities inhibit the progression of talented female staff, they in turn are unable to reach their full potential. We know that universities make a huge contribution to society through research, teaching and partnerships with businesses, among many other activities.’ Professor Dame Athene Donald, Professor of Experimental Physics and Master of Churchill College, University of Cambridge WomenCount are very grateful to Perrett Laver for their support, the Government Equalities Office for their enagagement and Imperial College London for hosting the launch of this report on 2 March 2016. Cover quotation: Sir Nicholas Montagu, Chair of Council, Queen Mary University of London. Published by WomenCount © March 2016, all rights reserved. www.women-count.org Designed and produced by Graffeg. WomenCount: Leaders in Higher Education 2016 Contents 3 Foreword 4 Executive summary 5 Introduction 6 Collective action 9 Collegial governance: diversity challenge or opportunity? 10 Governing bodies: women’s representation on the rise 11 Governing bodies: the balancing act 12 Chairs: few seats for women 14 Vice-Chancellors: barely a fifth are women 15 Chair and Vice-Chancellor teams 16 Executive teams: a pipeline of women leaders 17 Academic heads: less than a third are women 19 HEI income impact women’s leadership 21 Mapping Women’s Leadership in HEIs 22 Reflections on the research 27 The Index 37 Biographies of new Chairs 42 Biographies of new Vice-Chancellors 47 About WomenCount and the author 1 Foreword ‘Gender equality is not a matter of being nice to women.
    [Show full text]
  • Carbon Dioxide Adsorption by Metal Organic Frameworks (Synthesis, Testing and Modeling)
    Western University Scholarship@Western Electronic Thesis and Dissertation Repository 8-8-2013 12:00 AM Carbon Dioxide Adsorption by Metal Organic Frameworks (Synthesis, Testing and Modeling) Rana Sabouni The University of Western Ontario Supervisor Prof. Sohrab Rohani The University of Western Ontario Graduate Program in Chemical and Biochemical Engineering A thesis submitted in partial fulfillment of the equirr ements for the degree in Doctor of Philosophy © Rana Sabouni 2013 Follow this and additional works at: https://ir.lib.uwo.ca/etd Part of the Other Chemical Engineering Commons Recommended Citation Sabouni, Rana, "Carbon Dioxide Adsorption by Metal Organic Frameworks (Synthesis, Testing and Modeling)" (2013). Electronic Thesis and Dissertation Repository. 1472. https://ir.lib.uwo.ca/etd/1472 This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of Scholarship@Western. For more information, please contact [email protected]. i CARBON DIOXIDE ADSORPTION BY METAL ORGANIC FRAMEWORKS (SYNTHESIS, TESTING AND MODELING) (Thesis format: Integrated Article) by Rana Sabouni Graduate Program in Chemical and Biochemical Engineering A thesis submitted in partial fulfilment of the requirements for the degree of Doctor of Philosophy The School of Graduate and Postdoctoral Studies The University of Western Ontario London, Ontario, Canada Rana Sabouni 2013 ABSTRACT It is essential to capture carbon dioxide from flue gas because it is considered one of the main causes of global warming. Several materials and various methods have been reported for the CO2 capturing including adsorption onto zeolites, porous membranes, and absorption in amine solutions.
    [Show full text]
  • Multinational Evaluation of Mycophenolic Acid, Tacrolimus
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE providedORIGINAL by University of QueenslandPAPER eSpace ISSN 1425-9524 © Ann Transplant, 2016; 21: 1-11 DOI: 10.12659/AOT.895664 Received: 2015.08.15 Accepted: 2015.09.01 Multinational Evaluation of Mycophenolic Published: 2016.01.05 Acid, Tacrolimus, Cyclosporin, Sirolimus, and Everolimus Utilization Authors’ Contribution: ABCDEF Kyle M. Gardiner School of Pharmacy, University of Queensland, Brisbane, QLD, Australia Study Design A ACDEF Susan E. Tett Data Collection B Statistical Analysis C ACDEF Christine E. Staatz Data Interpretation D Manuscript Preparation E Literature Search F Funds Collection G Corresponding Author: Christine E. Staatz, e-mail: [email protected] Source of support: Departmental funding only Background: Increasing immunosuppressant utilization and expenditure is a worldwide challenge as more people success- fully live with transplanted organs. Our aims were to characterize utilization of mycophenolate, tacrolimus, cy- closporin, sirolimus, and everolimus in Australian transplant recipients from 2007 to 2013; to identify specific patterns of usage; and to compare Australian utilization with Norwegian, Danish, Swedish, and the Netherlands use. Material/Methods: Australian utilization and expenditure data were captured through national Pharmaceutical Benefits Scheme and Highly Specialized Drug administrative databases. Norwegian, Danish, Swedish, and the Netherlands uti- lization were retrieved from their healthcare databases. Utilization was compared as defined daily dose per 1000 population per day (DDD/1000 population/day). Data on kidney transplant recipients, the predominant patient group prescribed these medicines, were obtained from international transplant registries. Results: From 2007–2013 Australian utilization of mycophenolic acid, tacrolimus and everolimus increased 2.7-fold, 2.2- fold, and 2.3-fold, respectively.
    [Show full text]
  • WHO Drug Information Vol 22, No
    WHO Drug Information Vol 22, No. 1, 2008 World Health Organization WHO Drug Information Contents Challenges in Biotherapeutics Miglustat: withdrawal by manufacturer 21 Regulatory pathways for biosimilar Voluntary withdrawal of clobutinol cough products 3 syrup 22 Pharmacovigilance Focus Current Topics WHO Programme for International Drug Proposed harmonized requirements: Monitoring: annual meeting 6 licensing vaccines in the Americas 23 Sixteen types of counterfeit artesunate Safety and Efficacy Issues circulating in South-east Asia 24 Eastern Mediterranean Ministers tackle Recall of heparin products extended 10 high medicines prices 24 Contaminated heparin products recalled 10 DacartTM development terminated and LapdapTM recalled 11 ATC/DDD Classification Varenicline and suicide attempts 11 ATC/DDD Classification (temporary) 26 Norelgestromin-ethynil estradiol: infarction ATC/DDD Classification (final) 28 and thromboembolism 12 Emerging cardiovascular concerns with Consultation Document rosiglitazone 12 Disclosure of transdermal patches 13 International Pharmacopoeia Statement on safety of HPV vaccine 13 Cycloserine 30 IVIG: myocardial infarction, stroke and Cycloserine capsules 33 thrombosis 14 Erythropoietins: lower haemoglobin levels 15 Recent Publications, Erythropoietin-stimulating agents 15 Pregabalin: hypersensitivity reactions 16 Information and Events Cefepime: increased mortality? 16 Assessing the quality of herbal medicines: Mycophenolic acid: pregnancy loss and contaminants and residues 36 congenital malformation 17 Launch
    [Show full text]
  • Refereed Publications (A = Article, C = Communication, R = Review)
    Curriculum Vitae: Douglas W. Stephan FRSC, FRS Current Address Department of Chemistry, University of Toronto, 80 St. George St. Toronto, ON, M5S3H6 [email protected]; [email protected] Phone: 416-946-3294; Cell: 647-339-3568; Admin. Asst: Shanna Pritchard 416-978-8940, [email protected] webpage: http://www.chem.utoronto.ca/staff/DSTEPHAN Home Address 47 St. Clair Ave. W., Suite 302, Toronto, ON. M4V 3A5; Home: 416-619-5901 Personal Born in Hamilton, Ontario, CANADA July 27 1953, married (Dianne L. Gunn) two adult children (David and Kathryn) Citizenship Canadian Education Ph.D 1980 (University of Western Ontario), B.Sc. 1976 (McMaster University, summa cum laude) Positions Held 2018-present University Professor, University of Toronto 2008-2018 Professor, University of Toronto 2016-2019 Chair, Editorial Board of Chemical Society Reviews 2016-2018 Einstein Visiting Fellow, TU Berlin. 2011-2017 Associate Editor, Chemical Society Reviews 2006 (Oct) International Research Guest Professor, WW-Universitaet Muenster 2008-2021 Canada Research Chair in Catalysis and New Materials (UToronto) 2005-2007 Canada Research Chair in Catalysis and New Materials (UWindsor) 2003-2006 Head, Department of Chemistry & Biochemistry 2002-2007 University Professor, University of Windsor 2002-2003 Humboldt Senior Awardee, WW-Universitaet Muenster 2001-2006 NSERC/NOVA Chemicals Corporation Industrial Research Chair 1995 DAAD Visiting Scientist, Muenster, Germany (declined) 1995 NSERC/DFG Visiting Scientist, WW-Universitaet Muenster. 1992-2002
    [Show full text]
  • Single-Purchase Product Guide Ebooks Connect Your Library Users to the Information They Need Most
    Single-purchase product guide eBooks Connect your library users to the information they need most over over over 1,300 25,000 480,000 books chapters pages eBook features Convenient online access • Books can be split by chapter to • MARC records and comprehensive usage read and download statistics, free of charge • Easy to use, powerful • Perpetual ownership search features • Unlimited access and usage • Downloads can be saved in • All titles DOI indexed to chapter level multiple formats Truly scalable Choose a package to suit your needs, or create one from scratch The complete collection Annual collections All 1,300 eBooks in one package Update your collection year by year Pick and Choose Subject collections Your pick of key titles, minimum spend £1,000 Smaller sets, focusing on specific topic areas Try before you buy... ...or start a conversation To access the first chapters of For more details on our eBook our entire eBook collection for packages contact your account free, visit manager or email rsc.li/echapters [email protected] Print books High quality, globally respected chemical science titles that span the breadth of our subject Book sets Collections of print books sorted by subject area or theme – a cost-effective way to get all the titles you need. Choose from 30 sets in a range of subjects, including: • Water • Green • Waste • General chemistry • Catalysis • Metals • Nanoscience • Neuroscience • Drug discovery • Agriculture and toxicology • Polymers • Energy • Computational Prices start from just £165. Browse the full range of book sets at rsc.li/bookset Specialist periodical reports: critical reviews of recent literature Specialist periodical reports (SPRs) are essential Contributing authors analyse, evaluate and for keeping on top of literature and current distil the latest progress in their specialist opinion in particular research fields.
    [Show full text]
  • Perspective Lecture, Frankfurt February 14Th 2013 Professor Paul
    Professor Paul Workman Bio: Perspective Lecture, Frankfurt February 14 th 2013 Professor Paul Workman – Short Biography Professor Paul Workman is a leader in the discovery and development of molecularly targeted cancer drugs and is a passionate advocate of personalized cancer therapy. A molecular pharmacologist and chemical biologist, Paul has been responsible for the discovery and development of a large number of new molecularly targeted cancer drugs. Paul is currently Deputy Chief Executive of The Institute of Cancer Research (ICR) and Director of the ICR’s Cancer Research UK Cancer Therapeutics Unit in Sutton, UK, which is the largest non-profit cancer drug discovery group worldwide. He is also Head of ICR’s Division of Cancer Therapeutics and Harrap Professor of Pharmacology and Therapeutics. Paul obtained his BSc (Hons) in Biochemistry from Leicester University (1973) and his PhD in Cancer Pharmacology from Leeds University (1977). He then moved to Cambridge to become a postdoctoral fellow and scientific staff member of the MRC Clinical Oncology Unit, MRC Centre, Cambridge University (1976-1990) where he established and led the cancer pharmacology group, making major contributions to drugs targeting tumour hypoxia. Following a period as UICC Visiting Fellow at Stanford University and SRI International, California (1989), Paul was appointed as Cancer Research Campaign Professor and Director of Laboratory Research in the Department of Medical Oncology, Beatson Laboratories, Glasgow University (1990-1993). Paul then gained experience in the pharmaceutical industry. From 1993-1997 Paul was Head of the Cancer Research Bioscience Section at AstraZeneca Pharmaceuticals, Alderley Park, UK where he also initiated and led the strategic alliance with Sugen.
    [Show full text]
  • Marc Corrales Berjano
    Text in context: Chromatin effects in gene regulation Marc Corrales Berjano TESI DOCTORAL UPF / 2017 DIRECTOR DE LA TESI Dr. Guillaume Filion DEPARTAMENT Gene Regulation, Stem cells and Cancer Genome architecture Center for Genomic Regulation (CRG) ii a mi familia, iii Aknowledgements I want to thank the members of the doctoral board, present and substitutes, for accepting to analize my work and defend my thesis. I also want to thank my thesis commitee Dr. Miguel Beato, Dr. Jordi Garcia-Ojalvo and Dr. Tanya Vavouri for guidance and valuable scientific imput whenever I needed it along these years. I want to thank my mentor Dr. Guillaume Filion, not only for giving me the opportunity to carry this work in a wonderful environement, but for teaching me. No matter the tigh schedule he has allowed me to sit by his side (literally) reviewing a script at the computer, calculating the probaility of plasmid recircularization or deriving a statistical formula at the white board but also helping me to prepare and electroporate a bacterial library in what seemed a contraction of space-time. I want to thank the community of the CRG, always ready to discuss science and life in the corridors, the data seminars, symposiums, the beer sessions or following a mail asking for advice or materials. People at the administration helped enormously to navigate the tortuous bureaucratic world, maximizing the time one can dedicate toscience. ¡Dónde estaría yo sin tu puerta siempre abierta, Imma, madre en funciones de todo phD student! I want to thank the CRG for funding my phD and for constituting what I envisage as the perfect environment to learn to be a scientist.
    [Show full text]
  • 2019 Annual Report
    BECKMAN CENTER 279 Campus Drive West Stanford, CA 94305 650.723.8423 Stanford University | Beckman Center 2019 Annual Report Annual 2019 | Beckman Center University Stanford beckman.stanford.edu 2019 ANNUAL REPORT ARNOLD AND MABEL BECKMAN CENTER FOR MOLECULAR AND GENETIC MEDICINE 30 Years of Innovation, Discovery, and Leadership in the Life Sciences CREDITS: Cover Design: Neil Murphy, Ghostdog Design Graphic Design: Jack Lem, AlphaGraphics Mountain View Photography: Justin Lewis Beckman Center Director Photo: Christine Baker, Lotus Pod Designs MESSAGE FROM THE DIRECTOR Dear Friends and Trustees, It has been 30 years since the Beckman Center for Molecular and Genetic Medicine at Stanford University School of Medicine opened its doors in 1989. The number of translational scientific discoveries and technological innovations derived from the center’s research labs over the course of the past three decades has been remarkable. Equally remarkable have been the number of scientific awards and honors, including Nobel prizes, received by Beckman faculty and the number of young scientists mentored by Beckman faculty who have gone on to prominent positions in academia, bio-technology and related fields. This year we include several featured articles on these accomplishments. In the field of translational medicine, these discoveries range from the causes of skin, bladder and other cancers, to the identification of human stem cells, from the design of new antifungals and antibiotics to the molecular underpinnings of autism, and from opioids for pain
    [Show full text]